Colonoscopy Before Age 50 May Cut Colorectal Cancer Risk in Women
MONDAY, May 9, 2022 -- Initiation of lower gastrointestinal endoscopy before 50 years of age is associated with a reduced risk for colorectal cancer (CRC) in women, according to a study published online May 5 in JAMA Oncology.
Wenjie Ma, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 9, 2022 Category: Pharmaceuticals Source Type: news
Real-World Evidence Supports Earlier Colorectal Cancer Screening Real-World Evidence Supports Earlier Colorectal Cancer Screening
Starting lower GI endoscopy before age 50 was associated with a significantly reduced risk of CRC, providing strong support for the updated CRC screening recommendations.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 5, 2022 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news
Endoscopic Obesity Treatments Offer Alternative to Surgery Endoscopic Obesity Treatments Offer Alternative to Surgery
While these methods have shown lower efficacy, they are associated with fewer adverse effects.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 27, 2022 Category: Endocrinology Tags: Gastroenterology News Source Type: news
Endoscopic Drainage Better for Necrotizing Pancreatitis
MONDAY, April 25, 2022 -- For patients with necrotizing pancreatitis, the rate of fistula formation and mortality is lower with endoscopic drainage (ED) than with other surgical drainage methods, according to a systematic review and meta-analysis... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 25, 2022 Category: Pharmaceuticals Source Type: news
The Truth About Common Digestive Health Fears
Everyone experiences digestive problems now and then, and they’re nobody’s idea of a good time. In a survey of nearly 72,000 adults in the U.S., 61% reported having had at least one gastrointestinal (GI) symptom over the previous week, and within that group, 58% said they’d had two or more GI symptoms over the past week, according to a study in a 2018 issue of the American Journal of Gastroenterology. Because symptoms like constipation, heartburn, and abdominal pain are generally vague and often don’t have an obvious cause, those suffering tend to fear the worst.
“People get very concerned abo...
Source: TIME: Health - March 14, 2022 Category: Consumer Health News Authors: Stacey Colino Tags: Uncategorized healthscienceclimate Source Type: news
What Are Common Gastrointestinal Polyposes in Children?
Discussion
Bloody stools or blood in the diaper is a relatively common complaint in general pediatrics. For most patients it is often a minor concern. Commonly it is a transient problem (e.g. rectal fissure caused by constipation or trauma) or often not blood (e.g. urate crystals in the diaper, food, menses, etc.). Real blood does occur with an identifiable cause such as long distance running or heavy exercise, or milk protein allergy/sensitivity that improves with a milk-restricted diet. Many more serious causes are associated with heavier or more recalcitrant bleeding, increased defecation, abdominal pain, poor eating an...
Source: PediatricEducation.org - January 24, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]<150) previously reported at week 12 increased at week 48 among adults with moderately to severely active Crohn’s disease (CD) treated with TREMFYA® (guselkumab).1 At week 48, 65 percent of patients receiving TREMFYA achieved clinical remission. TREMFYA is under investigation and not currently approved for the treatment of CD in the U.S.2Janssen previously...
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news
New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA ® (ustekinumab) in Older Patients Across Approved Indications
SPRING HOUSE, PENNSYLVANIA, October 4, 2021 – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials.1,b Approved indications included adults with moderately to severely active Crohn’s disease (CD), moderately to severely active ulcerative colitis (UC), moderate to severe plaque psoriasis (P...
Source: Johnson and Johnson - October 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
The application of plan, do, check, act (PDCA) quality management in reducing nosocomial infections in endoscopy rooms: It does work
Background: The role of plan, do, check, act (PDCA) cycle quality management in reducing nosocomial infections in endoscopy rooms remains unclear; we aimed to evaluate the effects of PDCA in the nosocomial infections control of endoscopy rooms.; Methods: This present study was a before and after design. The patients treated in our endoscopy room from 1 January 2019 to 31 December 2019 were included in the control group, which were managed according to current department practice. The patients from 1 January 2020 to 31 December 2020 were included in the PDCA group, which were managed according to PDCA cycle quality manageme...
Source: Current Awareness Service for Health (CASH) - September 10, 2021 Category: Consumer Health News Source Type: news
Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn ’s Disease
SPRING HOUSE, PENNSYLVANIA, May 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),1-4including data from the SEAVUE study, the first head-to-head study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session.1 SEAVUE data showed treatment with STELARA demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response and endoscopic response through one year in biologic-naïve patients with mo...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Screening Endoscopy May Lower CRC-Related Mortality in Healthy Elderly
FRIDAY, May 21, 2021 -- For individuals older than 75 years who do not have cardiovascular disease or significant comorbidities, screening endoscopy is associated with a lower risk for colorectal cancer (CRC)-related mortality, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 21, 2021 Category: Pharmaceuticals Source Type: news
No Benefit Seen for Rushing Endoscopy in Some High-Risk GI Patients No Benefit Seen for Rushing Endoscopy in Some High-Risk GI Patients
Performing endoscopy during the first six hours after a patient with gastrointestinal bleeding is handed off to a specialist does not lower the 30-day mortality rate compared to procedures done six to 24 hours after consultation, according to a new study of 516 volunteers reported in Thursday ' s New England Journal of Medicine.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 2, 2020 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
Endoscopy Within Six Hours Does Not Lower Mortality in GI Bleed
WEDNESDAY, April 1, 2020 -- Endoscopy within six hours versus six to 24 hours after consultation is not associated with lower 30-day mortality in patients with acute upper gastrointestinal bleeding who are at high risk for further bleeding or death,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 2, 2020 Category: Pharmaceuticals Source Type: news
Minimally Invasive Surgery Through the Eyes of a Surgeon
One of the best parts of an event like MD&M West is the opportunity to put a cross-section of experts from industry in the same room as engineers and end-users and talk about the biggest trends in medical devices. One such discussion that took place here in Annaheim, CA on Tuesday included an expert robotic surgeon, an expert from Intuitive Sugical (which, as you likely know by now, pioneered robotic surgery a little more than 20 years ago), and a new robotic surgery company that is trying to to take this technology beyond the surgical suite.
I shared a few insights from this lively panel discussion here, but prior to...
Source: MDDI - February 11, 2020 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news
New Sleep Apnea Treatment Offers CPAP Alternative - Inspire
dg62@duke.eduThu, 10/17/2019 - 10:07
Hero Image
Preview Image
Treatment TermsSleep disordersSleep Apnea
CategoriesSleep Disorders
Pin to Top of WiFi PageOff
Display in Announcement SectionOff
CTA ButtonSleep Apnea
Featured Doctors and ProvidersMatthew D. Ellison, MD
CTA HeaderLearn More About
Medically Reviewed DateTue, 09/03/2019 - 12:00
ArchivedOff
ReviewerMatthew Ellison
GenderFemale
Is Patient ExperienceOff
Expire DateFri, 09/02/2022 - 12:00
Blog Content Blocks
Section FeaturesText Content
HeaderWhy a New Approach to Treating Sleep Apnea Is Needed
ContentThe most...
Source: dukehealth.org: Duke Health News - October 17, 2019 Category: Consumer Health News Authors: dg62 at duke.edu Source Type: news
